Assists post-exercise recovery
9.6%).21 A meta-analysis of 16 RCTs of orlistat 120 mg 3 times daily ( n = 10 631 participants) reported a mean placebo-subtracted weight change of 2.9% (95% CI 3.4% to 2.5%) at 1 year.53 The most common adverse effects with orlistat included oily stool, fecal urgency, and spotting, occurring in 15%30% of patients and leading to discontinuation in some cases.53 Further details on efficacy, potential adverse effects, contraindications, and potential medication interactions are available in Appendix 1, and are reviewed in greater detail in the full guideline on the Obesity Canada website.7 Long-term treatment After weight loss with pharmacotherapy Obesity medications are intended as part of a long-term treatment strategy (Table 1, recommendation 4)
Involve the introduction of special substances that break down fat cells under the influence of ultrasound waves
Production of biologically active non-woven textiles from recycled polyethylene terephthalate
In vitro and preclinical studies indicate that cagrilintide retains high potency across amylin and calcitonin receptor subtypes and demonstrates additive pharmacodynamic effects when combined with GLP-1 agonists like semaglutide (DAscanio et al
Unopened items may qualify for store credit within 14 days of delivery
